Atreca Inc. Stock News

Brokerages expect that Atreca, Inc. (NASDAQ:BCEL) will announce ($0.75) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Atrecas earnings, with estimates ranging from ($0.83) to ($0.69). Atreca reported earnings of ($0.63) per share in the same quarter last year, which would suggest a negative year-over-year []

Geode Capital Management LLC decreased its position in shares of Atreca, Inc. (NASDAQ:BCEL) by 1.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 449,553 shares of the companys stock after selling 5,659 shares during the quarter. Geode Capital Management LLCs holdings in Atreca []

Atreca announced preliminary results using ATRC-101 in a phase 1b study treating patients with advanced solid tumors. One expansion cohort will include the combination of ATRC-101 and Keytruda which a

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d

SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d

BCEL has very high smart money involvement. Poor adverse event data brought the stock down in July.

SAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique

SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d

SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d

The stock price of Atreca Inc (NASDAQ: BCEL) fell by over 38% during intraday trading. This is why it happened.

Conference call and webcast scheduled for Thursday, July 29th at 8:00 a.m. ET Conference call and webcast scheduled for Thursday, July 29th at 8:00 a.m. ET

SAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di

Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since

SAN CARLOS Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique dis

REDWOOD CITY, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery pla